Widely used:Recently Viewed
Clear All
$223 Mln
--
2.32
--
0.26
-107.4 %
--
--
--
-347320
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adaptimmune Therapeutics (ADAP)
| 10.86 | -20.80 | -31.32 | 34.01 | -45.53 | -3.67 | -- |
|
BSE Sensex*
| 13.15 | -1.39 | 1.52 | 23.32 | 10.06 | 16.42 | 11.99 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Adaptimmune Therapeutics (ADAP)
| -45.68 | -61.07 | -30.43 | 349.17 | -79.13 | -13.85 | 64.94 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$222.91 Mln
$141.60 Mln
$-45.60 Mln
$214.79 Mln
$47.35 Mln
Low
$0.42 - 2.05
255,744,992
NASDAQ: ADAP
Abingdon
https://www.adaptimmune.com
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with... ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX Read more
The total asset value of Adaptimmune Therapeutics plc (ADAP) stood at $ 404 Mln as on 30-Jun-24
The share price of Adaptimmune Therapeutics plc (ADAP) is $0.88 (NASDAQ) as of 14-Oct-2024 16:27 EDT. Adaptimmune Therapeutics plc (ADAP) has given a return of -45.53% in the last 3 years.
Adaptimmune Therapeutics plc (ADAP) has a market capitalisation of $ 223 Mln as on 14-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Adaptimmune Therapeutics plc (ADAP) is 2.32 times as on 14-Oct-2024, a 25% discount to its peers’ median range of 3.10 times.
Since, TTM earnings of Adaptimmune Therapeutics plc (ADAP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adaptimmune Therapeutics plc (ADAP) and enter the required number of quantities and click on buy to purchase the shares of Adaptimmune Therapeutics plc (ADAP).
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
The CEO & director of Mr. Adrian G. Rawcliffe. is Adaptimmune Therapeutics plc (ADAP), and CFO & Sr. VP is Mr. Adrian G. Rawcliffe.
There is no promoter pledging in Adaptimmune Therapeutics plc (ADAP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,048
|
|
|
988
|
|
|
965
|
|
|
900
|
| Adaptimmune Therapeutics plc (ADAP) | Ratios |
|---|---|
|
Return on equity(%)
|
-107.4
|
|
Operating margin(%)
|
-62.76
|
|
Net Margin(%)
|
-51.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adaptimmune Therapeutics plc (ADAP) was $-46 Mln.
$0.01
